[Clinical experience with heparinoid sodium pentosan polysulfate (SP54) in the treatment of cerebral ischemia].
Fifty-five patients suffering from acute cerebral ischaemia were treated with pentosan polysulphate (SP54) intravenously and subsequently orally. The control group consisting of 35 patients received the infusion solution and vasodilator drugs. The statistically significant changes appearing following infusion of SP54 include the following parameters: haematocrit, blood viscosity and cholesterol concentrations. In individual cases the euglobulin lysis time was shortened within two hours after the beginning of the infusion. As demonstrated by the statistically reliable results in patients treated with SP54 the neurological symptoms improved significantly within the first two weeks after the onset of the disease compared to the control groups. Based on case reports, recommendations are given for the indication and contraindication of SP54 treatment in cerebral ischaemia.
D000284:Administration, Oral; D001809:Blood Viscosity / Q000187:drug effects; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D006400:Hematocrit; D006493:Heparin; D006801:Humans; D007263:Infusions, Parenteral; D010426:Pentosan Sulfuric Polyester / Q000008:administration & dosage / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use*
D011134:Polysaccharides; D010426:Pentosan Sulfuric Polyester; D006493:Heparin; D002784:Cholesterol
Klinische Erfahrungen mit dem Heparinoid Natrium-Pentosanpolysulphat (SP54) bei der Behandlung zerebraler Ischämien.